Omeros (NASDAQ:OMER) Stock Rating Lowered by Zacks Research

Omeros (NASDAQ:OMER) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

A number of other research analysts have also recently commented on the company. D. Boral Capital restated a “buy” rating and issued a $36.00 price target on shares of Omeros in a research report on Tuesday, April 21st. Weiss Ratings downgraded shares of Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 2nd. HC Wainwright reduced their price objective on shares of Omeros from $40.00 to $33.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Finally, Wall Street Zen cut Omeros from a “buy” rating to a “hold” rating in a report on Sunday, June 7th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Omeros Trading Up 4.9%

Shares of Omeros stock opened at $10.50 on Monday. The company has a market capitalization of $759.99 million, a PE ratio of 15.00 and a beta of 2.55. The stock’s fifty day simple moving average is $10.95 and its 200 day simple moving average is $11.84. Omeros has a 12 month low of $3.34 and a 12 month high of $17.65.

Omeros (NASDAQ:OMER) last announced its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.16. The business had revenue of $9.89 million for the quarter, compared to analyst estimates of $4.19 million. Analysts predict that Omeros will post -0.94 EPS for the current fiscal year.

Insider Buying and Selling

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $11.61, for a total transaction of $87,075.00. Following the sale, the director owned 35,067 shares in the company, valued at $407,127.87. This trade represents a 17.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Omeros

Several large investors have recently added to or reduced their stakes in OMER. UBS Group AG increased its position in Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after buying an additional 1,513,893 shares in the last quarter. Vanguard Group Inc. increased its holdings in Omeros by 19.9% during the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after buying an additional 666,357 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Omeros by 1,201.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock worth $1,706,000 after purchasing an additional 384,168 shares during the period. State Street Corp lifted its stake in shares of Omeros by 26.9% during the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock valued at $27,025,000 after buying an additional 333,798 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Omeros by 39.3% during the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after purchasing an additional 263,095 shares in the last quarter. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.